দেশ: মাল্যাশিয়া
ভাষা: ইংরেজি
সূত্র: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
Latanoprost
DUOPHARMA (M) SDN. BHD.
Latanoprost
2.5 ml
DUOPHARMA (M) SDN. BHD.
_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP) _ 1 LATANOST EYE DROPS 0.005% Latanoprost 0.005% WHAT IS IN THE LEAFLET 1. What LATANOST is used for 2. How LATANOST works 3. Before you use LATANOST 4. How to use LATANOST 5. While you are using it 6. Side effects 7. Storage and Disposal of LATANOST 8. Product Description 9. Manufacturer 10. Product Registration Holder 11. Date of Revision WHAT LATANOST IS USED FOR LATANOST is used to treat eye conditions that are linked to an increase in the pressure within the eye (open angle glaucoma, chronic angle closure glaucoma and ocular hypertension) in adult, that can eventually affect your eyesight. LATANOST is also used to treat increased eye pressure and glaucoma in children HOW LATANOST WORKS LATANOST contains Latanoprost which is belongs to a group of medicines known as prostaglandin analogues. LATANOST works by increasing the natural outflow of fluid from inside the eye into the bloodstream and thus reducing the eye pressure. BEFORE YOU USE LATANOST - _When you must not take it_ _ _ Do not start using LATANOST if you or your child is allergic (hypersensitive) to latanoprost or any of the other ingredients of LATANOST If you are not sure whether you should start taking this medicine, talk to your doctor or pharmacist. _Pregnancy and lactation _ Tell your doctor immediately if you are pregnant, think you are pregnant, or are planning to become pregnant. Your doctor will discuss the possible risks and benefits of using LATANOST during pregnancy. LATANOST should be used with caution if you are breastfeeding. Ask your doctor or pharmacist for advice before using LATANOST if you are breastfeeding. - _Before you start to use it _ Check with your doctor or pharmacist before using LATANOST if you think any of the following applies to you. The same applies if your child has been prescribed LATANOST. - If you or your child suffer from eye problem (such as absence of the lens in the eye, or presence of artificial lens) - If you or your child have severe asthma or if the asthma সম্পূর্ণ নথি পড়ুন
[DUOPHARMA (M) SDN BHD] Page 1 of 3 Revision Date: 06.07.2020 LATANOST EYE DROPS 0.005% DESCRIPTION: LATANOST EYE DROPS 0.005%: A clear, colourless solution. COMPOSITION: Each 1 ml contains 50 mcg of latanoprost. Contains preservative: benzalkonium chloride 0.2 mg/ml. PHARMACODYNAMICS: Pharmacotherapeutic group: Ophthalmologicals; Antiglaucoma preparations and miotics, prostaglandin analogues. ATC code: S 01 E E 01 The active substance latanoprost, a prostaglandin F2α analogue, is a selective prostanoid FP receptor agonist which reduces the IOP by increasing the outflow of aqueous humour. Reduction of the IOP in man starts about three to four hours after administration and maximum effect is reached after eight to twelve hours. Pressure reduction is maintained for at least 24 hours. Studies indicated that the main mechanism of action is increased uveoscleral outflow, although some increase in outflow facility (decrease in outflow resistance) has been reported in man. PHARMACOKINETICS: Absorption Latanoprost (mw 432.58) is an isopropyl ester prodrug which per se is inactive, but after hydrolysis to the acid of latanoprost becomes biologically active. The prodrug is well absorbed through the cornea and all drug that enters the aqueous humour is hydrolysed during the passage through the cornea. Distribution The peak concentration in the aqueous humour is reached about two hours after topical administration. Biotransformation and elimination There is practically no metabolism of the acid of latanoprost in the eye. The main metabolism occurs in the liver. The half-life in plasma is 17 minutes in man. The main metabolites, the 1,2- dinor and 1,2,3,4-tetranor metabolites, exert no or only weak biological activity in animal studies and are excreted primarily in the urine. INDICATIONS: ▪ Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma, chronic angle closure glaucoma and ocular hypertension ▪ Reduction of elevated intraocular pressure in paediatric patients with elevated intraocula সম্পূর্ণ নথি পড়ুন